文献速递炎症性肠病

瘘管型克罗恩病药物治疗疗效的系统综述与荟萃分析

Efficacy of Medical Therapies for Fistulizing Crohn's Disease: Systematic Review and Meta-analysis.
PubMed 文献 · Clin Gastroenterol Hepatol · 2018-01-31

该系统综述与荟萃分析纳入截至2016年12月13日的27项随机对照试验,评估药物治疗瘘管型克罗恩病的疗效。结果显示,肿瘤坏死因子拮抗剂对肛周瘘管缓解的诱导和维持有效(RR 2.01;95%CI 1.36-2.97,中等质量证据),乌司奴单抗和间充质干细胞治疗也有一定疗效但置信区间跨1。

要点

  • 肿瘤坏死因子拮抗剂对肛周瘘管缓解的诱导和维持有效(RR 2.01;95%CI 1.36-2.97,中等质量证据)。
  • 乌司奴单抗(RR 1.77;95%CI 0.93-3.37)和间充质干细胞治疗(RR 1.31;95%CI 0.98-1.73)用于诱导瘘管缓解的证据质量中等。
  • 维得利珠单抗和免疫抑制剂疗效的证据质量低;肿瘤坏死因子拮抗剂联合抗生素优于单用肿瘤坏死因子拮抗剂的证据质量低。

核心结论

  • 在27项对照试验的系统综述与荟萃分析中,肿瘤坏死因子拮抗剂对肛周瘘管反应和缓解的诱导和维持有效。
  • 关于内部瘘管影响的数据很少,尤其需要针对乌司奴单抗、维得利珠单抗和干细胞治疗在瘘管型克罗恩病患者中的进一步研究。

研究设计与样本

  • 系统综述与荟萃分析,检索建库至2016年12月13日的文献数据库,纳入比较治疗药物(单药或联合)与安慰剂或其他活性药物治疗成人任何形式瘘管型克罗恩病的随机对照试验。
  • 共分析27项试验,多数研究(21/27)聚焦于肛周瘘管型克罗恩病患者;使用Cochrane偏倚风险工具评估方法学质量,采用GRADE评估证据总体质量。

主要发现

  • 肿瘤坏死因子拮抗剂诱导瘘管缓解的合并RR为2.01(95%CI 1.36-2.97),证据质量中等。
  • 乌司奴单抗诱导瘘管缓解的RR为1.77(95%CI 0.93-3.37),间充质干细胞治疗的RR为1.31(95%CI 0.98-1.73),证据质量中等。
  • 维得利珠单抗和免疫抑制剂疗效的证据质量低。
  • 肿瘤坏死因子拮抗剂联合抗生素对比单用肿瘤坏死因子拮抗剂有效的证据质量低。

关键数值与推荐

  • 主要结局包括瘘管反应和缓解的诱导与维持,计算各结局的合并风险比(RR)和95%CI。
  • 肿瘤坏死因子拮抗剂诱导瘘管缓解:RR 2.01(95%CI 1.36-2.97),中等质量证据。
  • 乌司奴单抗诱导瘘管缓解:RR 1.77(95%CI 0.93-3.37),中等质量证据。
  • 间充质干细胞治疗诱导瘘管缓解:RR 1.31(95%CI 0.98-1.73),中等质量证据。

临床怎么用

  • 肿瘤坏死因子拮抗剂可用于肛周瘘管型克罗恩病反应和缓解的诱导和维持(中等质量证据)。
  • 乌司奴单抗和间充质干细胞治疗用于诱导瘘管缓解的证据质量中等,但置信区间跨1,未达统计学显著。
  • 维得利珠单抗、免疫抑制剂及肿瘤坏死因子拮抗剂联合抗生素的证据质量低。
  • 关于内部瘘管影响的数据很少,尤其需要针对乌司奴单抗、维得利珠单抗和干细胞治疗的进一步研究。

局限性

  • 关于内部瘘管影响的数据很少。
  • 尤其需要针对乌司奴单抗、维得利珠单抗和干细胞治疗在瘘管型克罗恩病患者中的进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Fistulas are debilitating complications of Crohn's disease (CD) that affect up to 50% of patients. We conducted a systematic review and meta-analysis of randomized controlled trials to assess the efficacy of treatments for fistulizing CD. METHODS: We searched publication databases from inception through December 13, 2016 for trials comparing the efficacy of a therapeutic agent (single or combination) with placebo or another active therapy in adult patients with any form of fistulizing CD. The Cochrane risk of bias tool was used to assess the methodological quality of trials; the overall quality of evidence was evaluated using GRADE. Primary outcomes included induction and maintenance of fistula response and remission. Pooled risk ratios (RRs) and 95% CIs were calculated for each outcome. RESULTS: We analyzed data from 27 trials; most studies (21/27) focused on patients with perianal fistulizing CD. We found moderate-quality evidence to support the efficacy of tumor necrosis factor (TNF) antagonists (RR, 2.01; 95% CI, 1.36-2.97), particularly infliximab, ustekinumab (RR, 1.77; 95% CI, 0.93-3.37), and mesenchymal stem cell therapy (RR, 1.31; 95% CI, 0.98-1.73) for induction of fistula remission. We found low-quality evidence for the efficacy of vedolizumab and immunosuppressives. There was also low-quality evidence to support the efficacy of combination therapy with TNF antagonists and antibiotics vs a TNF antagonist alone. CONCLUSION: In a systematic review and meta-analysis of 27 controlled trials, we found TNF antagonists to be effective for induction and maintenance of perianal fistula response and remission. There are few data on the effects on internal fistulae. Further studies are needed, particularly for ustekinumab, vedolizumab, and stem cell therapies, in patients with fistulizing CD.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Lee MJ, Parker CE, Taylor SR, et al. Efficacy of Medical Therapies for Fistulizing Crohn's Disease: Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2018. PMID: 29374617. doi:10.1016/j.cgh.2018.01.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。